Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Park, J.; Finn, R.; Cheng, A.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K.; Harding, J.; Merle, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
    Meeting Abstract

    El-Khoueiry, A.; Meyer, T.; Cheng, A.; Rimassa, L.; Sen, S.; Milwee, S.; Kelley, R.; Abou-Alfa, G.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)
    Meeting Abstract

    Velez, L.; Trevino, T.; Kopetz, S.; Grothey, A.; Yaeger, R.; Gollerkeri, A.; Maharry, K.; Tabernero, J.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
    Meeting Abstract

    Patel, M.; Siena, S.; Demetri, G.; Doebele, R.; Chae, Y.; Conkling, P.; Garrido-Laguna, I.; Longo, F.; Rolfo, C.; Sigal, D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
    Meeting Abstract

    Kelley, R.; Kudo, M.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y.; Qin, S.; Tai, D.; Lim, H.; Yau, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial
    Meeting Abstract

    Abou-Alfa, G.; Borbath, I.; Cohn, A.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D.; Roychowdhury, S.; Sadeghi, S.; Shroff, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers
    Meeting Abstract

    Harding, J.; Hofheinz, R.; Elez, E.; Kuboki, Y.; Geng, J.; Schmohl, M.; Dowling, E.; Feng, Y.; Rasco, D.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1
    Meeting Abstract

    Sangro, B.; Kudo, M.; Qin, S.; Ren, Z.; Chan, S.; Joseph, E.; Arai, Y.; Mann, H.; Morgan, S.; Cohen, G.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial
    Meeting Abstract

    Kindler, H.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M.; Park, J.; Hochhauser, D.; Arnold, D.; Oh, D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis
    Meeting Abstract

    Javle, M.; Sadeghi, S.; Roychowdhury, S.; El-Khoueiry, A.; Goyal, L.; Philip, P.; Kelley, R.; Borbath, I.; Macarulla, T.; Yong, W.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save